Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Madrigal Pharmaceuticals, Inc. on June 20, 2025. The filing details the outcomes of shareholder votes regarding director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (April 24, 2025), 22,203,282 shares were outstanding, with 20,427,421 shares present to vote. Key outcomes include:
- Director Elections: Stockholders re-elected four Class III directors (Julian C. Baker, Raymond Cheong, Jacqualyn A. Fouse, and Richard S. Levy) to serve until the 2028 annual meeting. All candidates received significant majority support.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: Stockholders approved the compensation of named executive officers on a non-binding advisory basis.
- Voting Frequency: Stockholders approved holding future advisory votes on executive compensation on an annual ("One Year") basis.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risks, contingencies, or unusual items. The Board of Directors confirmed it will hold annual advisory votes on executive compensation based on the shareholder results.
Important Facts for Investors to Verify
- Confirmation that PricewaterhouseCoopers LLP will serve as the independent auditor for the fiscal year ending December 31, 2025.
- The composition of the Board of Directors following the re-election of the Class III directors.
- The Board's commitment to annual "Say on Pay" votes as determined by the shareholder advisory vote.
- Shareholder engagement levels, noting that approximately 92% of outstanding shares were represented at the meeting.